Background. Erythropoietin is available as a therapeutic agent produced by recombinant DNA technology in mammalian cell culture. It is used in treating anemia of prematurity. Repretina is one of the forms of erythropoietin as biomedicine. Material and metods: The study reveals the dynamic evaluation of hematological indicators: hemoglobin, hematocrite, the reticulocytes, as well as the number of early and late transfusions at the lot of 30 VLBW newborns who have benefited from the treatment with repretin in comparison with 30 newborns of the same anthropometric indicators who have followed the treatment with iron for early premature anemia. Results: The treatment was starting at end of first week of life with doze of 600 UN/KG/WEEK, divided in 3 dozes, subcutaneus in term of 6 weeks or untill 37 weeks of gestation. The treatment with iron drugs was started at end of first weeks of life with dose of 0.5 mg/kg/day with progressive increase of doze until 6-8mg/kg/day for 10-15 day. And asociated with folic lead 2.5 mg/day, vitamine E 15 mg/day. The treatment was initiated when enteral alimentation was over 20ml/kg/day >75Kcal/kg/day The martor group start treatment with iron drug at 3 weeks of life 6mg/kg.day, folic lead 2.5 mg/kg/day, vitamine E. Monitoring was efectuated trought determine hematological parameters HB, HT, reticolocyte at 10 days, 1 mounth, 2 mounths, 37 weeks postconceptional. The precoce hemotransfusion was considering untill 15 days of life and tardive after 15 days postnatal. The semnificative diference between thouse 2 group apeare at 1 month of live with superior level of HB, HT wich received repretine at 2 month of life and 37 weeks of gestation. Conclusions: The administration of repretin improves significantly the dynamics of hematological indicators and considerably reduces the need in late transfusions.Treatment with repretin have a good point in calitative superior transfusion program.